Evidence map›Paper›PMID 35388133›Full record

ArticleScientific reports2022

The prognostic value of the Naples prognostic score for patients with non-small-cell lung cancer.

Si-Min Peng, Jin-Jin Ren, Na Yu, Jia-Ying Xu, Guo-Chong Chen, Xiaodong Li, Da-Peng Li, Jing Yang, Zeng-Ning Li, Yu-Song Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Si-Min PengDepartment of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, China.
Jin-Jin RenDepartment of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, China.
Na YuDepartment of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Jia-Ying XuState Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Soochow University, Suzhou, China.
Guo-Chong ChenDepartment of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, China.
Xiaodong LiDepartment of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, China.
Da-Peng LiDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jing YangDepartment of Clinical Nutrition, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zeng-Ning LiDepartment of Nutrition, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Yu-Song ZhangDepartment of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China. zhangyusong19@163.com.
Li-Qiang QinDepartment of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, China. qinliqiang@suda.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Naples prognostic score (NPS) is an effective inflammatory and nutritional scoring system widely applied as a prognostic factor in various cancers. We aimed to analyze the prognostic value of the NPS in patients diagnosed with non-small-cell lung cancer (NSCLC). We prospectively collected 395 patients diagnosed with NSCLC between January 2016 and December 2018 in two university-affiliated hospitals. Patients were divided into three groups according to their pretreatment NPS (Group 0: NPS = 0; Group 1: NPS = 1-2; Group 2: NPS = 3-4). Kaplan-Meier survival curves indicated that patients with higher NPS had a poorer overall survival (OS) and progress-free survival (PFS) (both P < 0.05). NPS was further confirmed as an independent prognostic factors of OS and PFS by multivariable survival analysis (both P < 0.05). Furthermore, stratifying by TNM stage, NPS also has significant predictive performance for OS and PFS in both early (I-IIIA) and advanced (IIIB-IV) stage NSCLC (all P < 0.05). The time-dependent receiver operating characteristic curve analysis demonstrated that NPS was more superior to other prognostic factors in predicting OS and PFS. In conclusion, NPS may serve as an effective indicator to predict OS and PFS in NSCLC patients regardless of TNM stage.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansKaplan-Meier EstimatePrognosisRetrospective Studies

Identifiers

PMID35388133
PMCPMC8986824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.